Summary & Overview
HCPCS Q5103: Injection, infliximab-dyyb (Inflectra), 10 mg
HCPCS Level II code Q5103 denotes the biosimilar product injection, infliximab-dyyb (Inflectra), in a 10 mg unit. This code is used to bill for the biosimilar monoclonal antibody product supplied for therapeutic infusion or injection and is relevant across outpatient infusion centers, hospital outpatient departments, and physician offices that administer biologic therapies. Nationally, biosimilar codes like Q5103 matter for managing biologic drug costs, facilitating substitution where permitted, and ensuring accurate product identification for coverage and payment.
Key payers in the comparative analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for infliximab biosimilars, payer coverage considerations, and the types of benchmarks and policy updates typically associated with HCPCS biosimilar codes. The publication outlines common billing practices for infusion services, payer authorization patterns, and coding considerations for units supplied versus administered.
The content provides actionable reference points for coding accuracy, claims submission, and reimbursement navigation without offering clinical guidance. It highlights where input data was complete and notes items that were not provided in the source material.
Billing Code Overview
HCPCS Level II code Q5103 describes the product injection, infliximab-dyyb, biosimilar (Inflectra), 10 mg. This code identifies a biosimilar formulation of infliximab supplied as a 10 mg unit for parenteral administration.
Service type: Therapeutic infusion/injection of a monoclonal antibody biosimilar.
Typical site of service: Outpatient infusion center, hospital outpatient department, or physician office where intravenous or subcutaneous biologic therapies are administered.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 52-year-old patient with moderate to severe Crohn disease presents to an outpatient infusion center for maintenance biologic therapy. The clinician has prescribed Q5103 (infliximab-dyyb, biosimilar, Inflectra) 10 mg vial dosing as part of an induction or scheduled maintenance infusion regimen. The patient arrives for pre-infusion nursing assessment, including vital signs, screening for active infections (tuberculosis symptoms review, recent exposure), and review of concomitant immunosuppressive medications.
The clinical workflow: the infusion nurse verifies the physician order and patient identity, documents baseline vitals and allergy history, obtains required pre-infusion labs if indicated (e.g., CBC, CMP), and prepares the biosimilar medication under sterile technique. The medication is administered intravenously per institutional infusion protocol (typically over 2 hours for first infusions, shorter for subsequent infusions if tolerated). During infusion the nurse monitors for infusion reactions (vital signs at regular intervals) and documents medication lot number and expiration. After completion, the patient is observed for a standard recovery period and discharged with follow-up instructions and the next scheduled infusion appointment. Billing uses Q5103 for the dispensed biosimilar product; administration and infusion services are billed separately with the appropriate CPT codes and applicable modifiers.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|